Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease
NCT06818266Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2025
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in acute chest syndrome (ACS), sponsored by Assistance publique - Hôpitaux de Paris. Started Aug 2025; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
acute chest syndrome (ACS)
Beyond the preview
Go deeper on NCT06818266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818266.